The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: The US experience

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 11, 2011, Pages 2229-2234

  Kurth, M ^a   Puetz, J ^b   Kouides, P ^c   Sanders, J ^d   Sexauer, C ^e   Bernstein, J ^f   Gruppo, R ^g   Manco Johnson, M ^h   Neufeld, E J ⁱ   Rodriguez, N ^j   Wicklund, B ^k   Quon, D ^l   Aledort, L ^m  

^a CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^b SSM Cardinal Glennon Children's Medical Center   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d Pediatric Cardiothoracic Surgery   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f Children's Center for Cancer and Blood Diseases   (United States)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k CHILDREN S MERCY HOSPITAL   (United States)

^l Orthapedic Hospital   (United States)

^m MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Factor concentrate; Hemophilia; Immune tolerance; Inhibitor; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADOLESCENT; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; HEMOPHILIA A; HUMAN; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SCHOOL CHILD; UNITED STATES;

CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG COMBINATIONS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; RETROSPECTIVE STUDIES; UNITED STATES; VON WILLEBRAND FACTOR;

EID: 80055106986     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04493.x     Document Type: Article

References (45)

1. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
3. Gruppo R, Bray GL, Schroth P, Perry M Gomperts ED, for the Recombinate PUP Study Group. Safety and immunogenicity of recombinant factor VIII (recombinate) in previously untreated patients (PUPS): a 6.5-year update. The Recombinate PUP Study Group (abstract). Thromb Haemost 1997; 162(Suppl.): PD-663.
4. Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
5. Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67.
6. Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilsson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 1550.
7. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001; 7: 33-8.
8. Eichinger S, Lubsczyk B, Kollars M, Traby L, Zwiauer K, Gleiss A, Quehenberger P, Kyrle PA. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. Eur J Clin Invest 2009; 39: 707-13.
9. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
10. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
11. DiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006; 12(Suppl 6): 81-5.
12. Hay CRM, Lee CA, Berntorp EE, Hoots WK. Inhibitors to factor VIII/IX: treatment of inhibitors - immune tolerance induction. In: Lee CA, Berntorp EE, Hoots WK, ed. Textbook of Hemophilia. Malden, MA: Blackwell Publishing Ltd, 2005: 74-9.
13. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000; 60: 547-54.
14. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
15. Lenting PJ, van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-60.
16. Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. Haemophilia 2007; 13(Suppl 5): 69-72.
17. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7: 1446-56.
18. Auerswald G, Spanger T, Brackmann H. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
19. Gringeri A, Musso R, Bernasconi S, Villar A, Brito D, Coppola A, Piseddu G, Prieto M, Santagostino E, Schiavoni M, Schinco PC. Immunotolerance induction (ITI) with a high purity FVIII/VWF concentrates in inhibitor patients with a high risk of a poor response to ITI: a prospective surveillance. J Thromb Haemost 2005; 3: OR207.
20. Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
21. Kreuz W, Joseph-Steiner J, Mentzer D. Successful immune tolerance therapy of FVIII-inhibitors in children after changing from high to intermediate purity FVIII concentrate. Ann Hematol 1996; 72: 339.
22. Kurth MA, Dimichele D, Sexauer C, Sanders JM, Torres M, Zappa SC, Ragni M, Leonard N. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
23. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
24. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
25. Corrected Minutes of International ITI Investigators Meeting; ASH 2009- New Orleans, December 6, 2009. Available at: Last accessed: 30 March 2011.
26. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
27. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
28. Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 1999; 81: 35-8.
29. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
30. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors--twenty years''bonn protocol'. Vox Sang 1996; 70(Suppl 1): 30-5.
31. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
32. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996; 70(Suppl 1): 2-8.
33. Mariani G, Scheibel E, Nogao T, Kasper CK, Ewing NP, Mauser-Bunschoten E, Ghirardini A, Bellocco R, Brackman HH. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol 1994; 31: 62-4.
34. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
35. Haya S, Lopez MF, Aznar JA, Batlle J. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
36. Lenk H. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85: 45-7.
37. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77(Suppl 1): 25-7.
38. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
39. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl 1): 33-7.
40. Carcao M, St LJ, Poon MC, Grunebaum E, Lacroix S, Stain AM, Blanchette VS, Rivard GE. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
41. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-22.
42. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-8.
43. Silvrstein A. Intracranial bleeding in hemophilia. Arch Neurol 1960; 3: 141-57.
44. Callaghan MU, Raipurkar M, Chitlur M, Warrier I, Lusher J. Immunte tolerance induction in 31 children with haemophilia A: is ITI less successfrul in African Americans? Haemophilia 2011; 17: 483-9.
45. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13(Suppl 5): 73-7.